Niagen Bioscience Inc (NAGE) Revenue History
Annual and quarterly revenue from 2007 to present
NAGE Revenue Over Time (2007–2025)
NAGE Revenue Growth History
15 of 17 years with positive growth- FY2007 revenue growth
- N/A
- FY2008 revenue growth
- N/A
- FY2009 revenue growth
- +28.2%
- FY2010 revenue growth
- +31.0%
- FY2011 revenue growth
- +7.2%
- FY2012 revenue growth
- +43.1%
- FY2013 revenue growth
- -12.5%
- FY2014 revenue growth
- +50.7%
- FY2015 revenue growth
- +16.8%
- FY2016 revenue growth
- +21.1%
- FY2017 revenue growth
- -2.1%
- FY2018 revenue growth
- +48.8%
- FY2019 revenue growth
- +46.7%
- FY2020 revenue growth
- +28.0%
- FY2021 revenue growth
- +13.8%
- FY2022 revenue growth
- +6.8%
- FY2023 revenue growth
- +16.0%
- FY2024 revenue growth
- +19.2%
- FY2025 revenue growth
- +29.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $31.5M | +3.3% |
| Q4 2025 | $33.8M | +16.2% |
| Q3 2025 | $34.0M | +32.9% |
| Q2 2025 | $31.1M | +36.8% |
| Q1 2025 | $30.5M | +37.6% |
| Q4 2024 | $29.1M | +37.4% |
| Q3 2024 | $25.6M | +31.2% |
| Q2 2024 | $22.7M | +11.9% |
Multi-year avg. share of annual revenue by fiscal quarter
NAGE Revenue Analysis (2007–2025)
Current Revenue & Growth
As of June 28, 2026, Niagen Bioscience Inc (NAGE) generated trailing twelve-month (TTM) revenue of $130.4 million, reflecting modest growth of +3.3% year-over-year. The most recent quarter (Q1 2026) recorded $31.5 million in revenue, down 7.0% sequentially.
Historical Growth Trajectory
NAGE's 5-year compound annual growth rate (CAGR) stands at +16.9%, indicating consistent double-digit revenue growth. The 3-year CAGR of +21.6% exceeds the 5-year average, indicating an acceleration in the most recent period. Niagen Bioscience Inc's highest annual revenue of $129.4 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including NRXP, HALO (+39.1% YoY), and NBIX (+28.6% YoY) — NAGE has underperformed the peer group in revenue growth. Compare NAGE vs NRXP →
NAGE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NAGECurrent | $130M | +3.3% | +16.9% | 11.0% | |
 NRXP | $1M | - | - | -1324.4% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% | |
 NBIX | $2.9B | +28.6% | +22.3% | 21.6% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
NAGE Historical Revenue Data (2007–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $129.4M | +29.9% | $83.2M | 64.3% | $14.3M | 11.0% |
| 2024 | $99.6M | +19.2% | $61.6M | 61.8% | $7.7M | 7.8% |
| 2023 | $83.6M | +16.0% | $50.8M | 60.8% | $-5,599,000 | -6.7% |
| 2022 | $72.0M | +6.8% | $42.8M | 59.4% | $-18,628,000 | -25.9% |
| 2021 | $67.4M | +13.8% | $41.5M | 61.5% | $-27,073,000 | -40.1% |
| 2020 | $59.3M | +28.0% | $35.3M | 59.5% | $-19,854,000 | -33.5% |
| 2019 | $46.3M | +46.7% | $25.8M | 55.7% | $-31,300,000 | -67.6% |
| 2018 | $31.6M | +48.8% | $16.1M | 50.9% | $-33,172,000 | -105.1% |
| 2017 | $21.2M | -2.1% | $10.5M | 49.4% | $-16,377,000 | -77.2% |
| 2016 | $21.7M | +21.1% | $10.4M | 48.0% | $-2,905,210 | -13.4% |
| 2015 | $17.9M | +16.8% | $7.5M | 42.1% | $-2,066,095 | -11.6% |
| 2014 | $15.3M | +50.7% | $5.3M | 34.8% | $-5,231,349 | -34.2% |
| 2013 | $10.2M | -12.5% | $3.1M | 30.8% | $-4,386,446 | -43.2% |
| 2012 | $11.6M | +43.1% | $2.3M | 19.6% | $-11,636,434 | -100.2% |
| 2011 | $8.1M | +7.2% | $2.5M | 30.5% | $-7,864,239 | -96.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NAGE — Frequently Asked Questions
Quick answers to the most common questions about buying NAGE stock.
Is NAGE's revenue growth accelerating or slowing?
NAGE revenue growth is slowing. TTM revenue is $130M, up +3.3% year-over-year — below the 5-year CAGR of +16.9%. The deceleration suggests maturing end-markets or increased competition.
What is NAGE's revenue history from 2007 to 2026?
Niagen Bioscience Inc (NAGE) revenue history spans 2007 to 2026. TTM revenue as of 2026 is $130M, growing at +3.3% YoY. The 5-year CAGR is +16.9%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is NAGE's long-term revenue growth rate (CAGR)?
Niagen Bioscience Inc's 5-year revenue CAGR of +16.9% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of +3.3% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for NAGE.
Why does NAGE's quarterly revenue fluctuate?
NAGE quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Niagen Bioscience Inc's revenue data from 2007 to 2026 shows full historical quarterly detail on this page.
How is NAGE's revenue distributed by segment?
NAGE reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does NAGE's revenue compare to industry peers?
Niagen Bioscience Inc (NAGE) with TTM revenue of $130M and +3.3% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.